The creator expresses surprise at KOD's price resurgence.
Source Post
4/6/26 - sorry for the wait!
Martin ShkreliApr 6, 2026
Martin Shkreli returns after an illness, discussing various topics including biotech deals, drug development, and personal health regimens. He touches on Seleno acquisition by Nurocran, Lightwave Logic, Amgen's execution, and mentions Biogen and Viatris with some commentary.
Linked Mentions
Tickers discussed in this post
Viatris looks overvalued to the creator, leading to a negative outlook.
The creator acknowledges the Biogen deal was attractive to many investors.
Amgen is an execution machine, and the creator is updating their model.
Linked Signals
Tracked calls opened from this post
VTRS
sell opened Apr 6, 2026
-22.62%